Cantargia enrols first patient in trial of nadunolimab for AML and MDS

by | Mar 13, 2025 | Clinical Trials | 0 comments

​ 

Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals with AML and MDS.

 Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals with AML and MDS. 

Submit a Comment

Your email address will not be published. Required fields are marked *